Friday 20th December 2024 |
Text too small? |
EBOS Group Limited (“EBOS”) advises that the First Pharmaceutical Wholesaler Agreement (the “Wholesaler Agreement”) has been signed by the Australian Government and the pharmaceutical wholesaler industry body, the National Pharmaceutical Services Association (NPSA).
The Wholesaler Agreement outlines the Australian Government’s funding for wholesalers that are part of the Community Service Obligation (“CSO”) until 31 December 2029 and operates alongside the 8th Community Pharmacy Agreement (“8th CPA”), which was executed between the Australian Government and the Pharmacy Guild on 3 June 2024.
EBOS would like to thank the Department of Health and Aged Care and the Federal Minister for Health and Aged Care, The Honourable Mark Butler MP, for their constructive engagement during negotiations and for acknowledging the role EBOS plays as part of Australia’s health system.
The Wholesaler Agreement provides for a modest funding increase from FY25 and a further increase from FY27. These changes address significant erosion of supply chain funding and mean that Australians will continue to receive the uninterrupted medicine distribution service they have come to rely on. EBOS reiterates its guidance for FY25 that the Group expects to generate Underlying EBITDA(1) of between $575m to $600m.
(1)Underlying EBITDA excludes amounts that are considered one off or non-recurring items.
For further information please contact:
Martin Krauskopf
Executive General Manager, Strategy and Mergers & Acquisitions
+61 3 9918 5555
Martin.Krauskopf@ebosgroup.com
Authorised for lodgement with NZX and ASX by Janelle Cain, General Counsel, EBOS Group Limited.
About EBOS Group
EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care brand owner, product marketer and distributor.
No comments yet
MWE - Suspension of Trading and Delisting
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b
December 18th Morning Report